Efficacy and Safety of Tangshen Formula on Patients with Type 2 Diabetic Kidney Disease: A Multicenter Double-Blinded Randomized Placebo-Controlled Trial
Authors:
Open Access
- 4 May 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (5) , e0126027
Abstract
Persons with diabetes are at high risk of developing diabetic kidney disease (DKD), which is associated with high morbidity and mortality. Current drug therapies for DKD, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are not entirely satisfactory. This study aimed to evaluate the additional benefit and safety of the Chinese herbal granule Tangshen Formula (TSF) in treating DKD. The study was designed as a six-center randomized, double-blind, placebo-controlled trial. From April 2007 through December 2009, 180 patients with DKD were enrolled. In addition to conventional treatment with ACEIs or ARBs, 122 participants were randomly assigned to receive TSF and 58 participants to receive placebo for 24 weeks. Primary outcome was urinary protein level, measured by urinary albumin excretion rate (UAER) for participants with microalbuminuria, 24-hour urinary protein (24h UP) for participants with macroalbuminuria. Secondary outcomes included renal function, serum lipids, quality of life, symptoms, and adverse events. After 24 weeks of treatment, no statistically significant difference in UAER (TSF −19.53 μg/min compared with placebo −7.01 μg/min, with a mean difference of −12.52 μg/min; 95%CI, −68.67 to 43.63, P = 0.696) was found between TSF and placebo groups. However, TSF displayed a statistically significant decrease in 24h UP (TSF−0.21 g compared with placebo 0.36 g, with a mean difference of −0.57g; 95%CI, −1.05 to −0.09, P = 0.024). Estimated glomerular filtration rate (eGFR) was improved in both patients with microalbuminuria and macroalbuminuria, with a mean difference of 15.51 ml/min/1.73 m2 (95%CI, 3.71 to 27.31), 9.01 ml/min/1.73 m2 (95%CI, −0.10 to 18.13), respectively. Other secondary outcomes showed no statistically significant difference between groups or in the incidence of adverse events. Based on conventional treatments, TSF appears to provide additional benefits compared with placebo in decreasing proteinuria and improving eGFR in DKD patients with macroalbuminuria. Nevertheless, further study is needed to evaluate TSF treating patients with microalbuminuria. Chinese Clinical Trial Registry ChiCTR-TRC-10000843Keywords
This publication has 44 references indexed in Scilit:
- Standards of Medical Care in Diabetes—2013Diabetes Care, 2012
- Rheum officinale (a traditional Chinese medicine) for chronic kidney diseaseCochrane Database of Systematic Reviews, 2012
- Astragalus Injection for Hypertensive Renal Damage: A Systematic ReviewEvidence-Based Complementary and Alternative Medicine, 2012
- Optimized project of traditional Chinese medicine in treating chronic kidney disease stage 3: A multicenter double-blinded randomized controlled trialJournal of Ethnopharmacology, 2012
- Ameliorative effect of diosmin, a citrus flavonoid against streptozotocin-nicotinamide generated oxidative stress induced diabetic ratsChemico-Biological Interactions, 2012
- Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysisAmerican Journal of Kidney Diseases, 2010
- Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trialEuropean Heart Journal, 2010
- Standards of medical care in diabetes-20062006
- Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2004
- Development of the World Health Organization WHOQOL-BREF Quality of Life AssessmentPsychological Medicine, 1998